Prolonged Progression-Free Survival Reinforces Tucatinib’s Potential for Patients with Advanced HER2+ Metastatic Breast Cancer
07 déc. 2017 16h05 HE
|
Cascadian Therapeutics, Inc.
SAN ANTONIO, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that tucatinib in combination with standard of...
Tucatinib Data in Multiple Tumor Types Presented at the European Society for Medical Oncology (ESMO) 2017 Congress
11 sept. 2017 06h00 HE
|
Cascadian Therapeutics, Inc.
Results from Pooled Analysis Support the Potential Utility of Tucatinib for Patients with HER2+ Metastatic Breast Cancer with Brain Metastases Data from Nonclinical Models Support Evaluation of...